Latest
Kanvas Biosciences Raises $48M in Series A to Advance Microbiome-Based Cancer TherapiesKanvas Biosciences Raises $48M in Series A to Advance Microbiome-Based Cancer Therapies|Woman Owned NYC and Pulse NYC Bring Women Leaders to the Center of AI Week New York 2026Woman Owned NYC and Pulse NYC Bring Women Leaders to the Center of AI Week New York 2026|SYPartners and Pulse NYC Bring Radical Imagination Studio to #AIWeekNY for AI-Era Leadership ConversationsSYPartners and Pulse NYC Bring Radical Imagination Studio to #AIWeekNY for AI-Era Leadership Conversations|AI Week NY: Magic EdTech’s UX Challenge Puts Trust at the Center of Product DesignAI Week NY: Magic EdTech’s UX Challenge Puts Trust at the Center of Product Design|Tessera Labs Raises $60M in Series A to Automate Enterprise System TransformationsTessera Labs Raises $60M in Series A to Automate Enterprise System Transformations|InstaSwitch Raises $4.7M in Seed Funding to Streamline Business Banking Account ActivationInstaSwitch Raises $4.7M in Seed Funding to Streamline Business Banking Account Activation|Scout Space Raises Up to $18M in Series A to Expand Space Domain Awareness InfrastructureScout Space Raises Up to $18M in Series A to Expand Space Domain Awareness Infrastructure|4D Path Secures Strategic Financing to Advance Physics-Based Cancer Prediction Platform4D Path Secures Strategic Financing to Advance Physics-Based Cancer Prediction Platform|Vastian Secures Strategic Investment from Bregal Sagemount to Expand Healthcare Compliance PlatformVastian Secures Strategic Investment from Bregal Sagemount to Expand Healthcare Compliance Platform|Altara Raises $7M in Seed Funding to Build AI Platform for Industrial Data IntelligenceAltara Raises $7M in Seed Funding to Build AI Platform for Industrial Data Intelligence|Kanvas Biosciences Raises $48M in Series A to Advance Microbiome-Based Cancer TherapiesKanvas Biosciences Raises $48M in Series A to Advance Microbiome-Based Cancer Therapies|Woman Owned NYC and Pulse NYC Bring Women Leaders to the Center of AI Week New York 2026Woman Owned NYC and Pulse NYC Bring Women Leaders to the Center of AI Week New York 2026|SYPartners and Pulse NYC Bring Radical Imagination Studio to #AIWeekNY for AI-Era Leadership ConversationsSYPartners and Pulse NYC Bring Radical Imagination Studio to #AIWeekNY for AI-Era Leadership Conversations|AI Week NY: Magic EdTech’s UX Challenge Puts Trust at the Center of Product DesignAI Week NY: Magic EdTech’s UX Challenge Puts Trust at the Center of Product Design|Tessera Labs Raises $60M in Series A to Automate Enterprise System TransformationsTessera Labs Raises $60M in Series A to Automate Enterprise System Transformations|InstaSwitch Raises $4.7M in Seed Funding to Streamline Business Banking Account ActivationInstaSwitch Raises $4.7M in Seed Funding to Streamline Business Banking Account Activation|Scout Space Raises Up to $18M in Series A to Expand Space Domain Awareness InfrastructureScout Space Raises Up to $18M in Series A to Expand Space Domain Awareness Infrastructure|4D Path Secures Strategic Financing to Advance Physics-Based Cancer Prediction Platform4D Path Secures Strategic Financing to Advance Physics-Based Cancer Prediction Platform|Vastian Secures Strategic Investment from Bregal Sagemount to Expand Healthcare Compliance PlatformVastian Secures Strategic Investment from Bregal Sagemount to Expand Healthcare Compliance Platform|Altara Raises $7M in Seed Funding to Build AI Platform for Industrial Data IntelligenceAltara Raises $7M in Seed Funding to Build AI Platform for Industrial Data Intelligence
Back to articles

Corus Orthodontists Secures C$20M Investment in Calgary

Some companies raise capital. Others raise eyebrows. Corus Orthodontists just raised $20M in institutional equity, and the interesting part is not the number. It is the timing, the structure, and the...

Some companies raise capital. Others raise eyebrows. Corus Orthodontists just raised $20M in institutional equity, and the interesting part is not the number. It is the timing, the structure, and the restraint. Founded in 2019 by Dr. Paul Helpard and 18 orthodontists who were tired of watching patient care get boxed in by spreadsheets, Corus has spent 5 years building something quieter and harder to copy. Doctor owned. Doctor led. Growth without surrender. That is a harder song to play, but it lasts longer in the set.

This is Corus’ first institutional equity investment, led by ATB Financial’s private equity arm alongside a prominent Canadian family office. Not tourists. Long term partners. The kind who understand that orthodontics is not about speed, it is about alignment. Financial, clinical, cultural. The company already has access to more than $100M in capital, backed by a $250M credit facility with CIBC, Scotiabank, and ATB Financial. The equity round is not about survival or flash. It is about optionality, liquidity for existing shareholders, and making room at the table for the next generation of Doctor Partners.

Dean Prevost stepped in as CEO in September 2024, bringing a résumé forged in telecom, technology, and large scale integration. Peter Bishop continues to keep the balance sheet sharp as CFO. Dr. Paul Helpard now operates as Founder and Strategic Advisor, which feels less like a step back and more like a widening of the lens. The board, chaired by Alan D. Torrie, blends operators, investors, and practicing orthodontists who actually know what a chairside decision feels like at 4:45 on a Thursday.

Corus is not selling scale as a costume. 65+ Doctor Partners. 75+ locations. 13 U.S. states. 5 Canadian provinces. 2 straight years of double digit organic growth. Those numbers matter, but the model matters more. Cash plus stock. Buy in instead of sell out. Local brands stay local. Doctors retain ownership of patient records. The company handles the gravity so clinicians can focus on the art. That is not rebellion. That is discipline.

This investment will flow into people, practices, and future partners who want equity with their autonomy. It is a signal to orthodontists who want growth without losing their name on the door, and to investors who know healthcare rewards patience more than noise. Corus is not trying to be loud. It is trying to be in tune, and in this market, that might be the most disruptive move of all.